[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515544":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":60,"collaborators":32,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":32,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":32,"enrollmentInfo":72,"targetDuration":32,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-steroidal anti-inflammatory drug (NSAID)","EXPERIMENTAL","Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 1.0 mL of ketorolac 15 mg\u002FmL (15 mg total of ketorolac).",[13],"Drug: Ketorolac",{"label":15,"type":16,"description":17,"interventionNames":18},"Corticosteroid","ACTIVE_COMPARATOR","Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 0.5 mL of triamcinolone 40 mg\u002FmL (20 mg total of triamcinolone).",[19],"Drug: Triamcinolone",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ketorolac","Intervention will be an injection containing 1.0 mL of ketorolac 15 mg\u002FmL (15 mg total of ketorolac).",[9],[27],"Toradol",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Triamcinolone","Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg\u002FmL (20 mg total of triamcinolone).",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Marco Rizzo, MD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Lindsey Hobbs","CONTACT","5072939765","hobbs.lindsey@mayo.edu",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-92.4699,44.02163,{"lat":55,"lon":54},[58],{"name":39,"role":40,"phone":59,"phoneExt":32,"email":42},"15072262669",{"type":36,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Marco Rizzo","Principal Investigator","100515544","phase-3-nsaid-injection-versus-corticosteroid-injection-for-basilar-thumb-arthritis-100515544",false,"NCT05992883","NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis","NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* Adults \\>40 years of age\n* Pain at the thumb base brought on by direct pressure (grind test) and with movement\n* Pain resistant to previous conservative management (including over the counter medications (ibuprofen\u002Facetaminophen), icing, splinting\u002Fbraces, or topical analgesics)\n* Radiological observation indicative of arthritis based on the Eaton-Littler classification system (stages 1 through 4)\n* Patient understands the protocol and signed the informed consent\n* Patient is covered by health insurance\n\nExclusion Criteria:\n\n* • Known allergy to either of the treatment products\n* Patient's analgesic treatment regimen or other modalities of managing symptoms\u002Fpain associated with their hand pathology was modified within four weeks before trial inclusion\n* Symptomatic Scaphoid-trapezial arthritis present\n* Localized or systemic infection\n* Previous thumb surgery on study thumb\n* Previous thumb injury on study thumb\n* Patient with inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis)\n* Severe and\u002For uncontrolled hypertension\n* De Quervain tendinopathy present\n* History of injection to the trapeziometacarpal joint on study thumb within the previous 6 weeks\n* Uncontrolled diabetes\n* Pregnant or lactating females. Female participants of childbearing potential must have a negative pregnancy test before the injection. Women without childbearing potential (ie., surgically sterile with hysterectomy and\u002For bilateral oophorectomy and\u002For bilateral salpingectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible to participate without completing a pregnancy test.\n* Immunodeficient patients\n* Patients that are currently using nicotine products, or who have quit in the last 12 months\n* Patients under guardianship, curatorship, or are otherwise not self-sufficient\n* Patients participating in another clinical research trial which interferes with this study protocol or outcomes\n* Patients unable to follow the protocol in the investigators' judgement.","ALL","40 Years",{"count":73,"type":74},240,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","The Researchers are trying to compare two different types of intraarticular injections (injection in the joint) for treating the symptoms of moderate to advanced basilar thumb arthritis. One injection is ketorolac (an NSAID) and the other is triamcinolone (a corticosteroid).",[80],"Thumb Osteoarthritis",[82,83,84,85,86],"Injection","Steroid","NSAID","Thumb Arthritis","CMC Arthritis","2026-02-19",{"date":89,"type":90},"2026-02-23","ACTUAL",{"date":92,"type":90},"2023-07-28",{"date":94,"type":74},"2026-12-31",{"name":5,"class":6},1]